Cycle on Aug 24, 2026

I will start by listing the active research threads and watches for this topic to see what questions are currently open or what events we are monitoring.

I will call the `market_view` tool to get the current public-market views, valuations, financial health, and latest news for the two dominant GLP-1 players, Eli Lilly (LLY) and Novo Nordisk (NVO).

I will also pull the market view for Novo Nordisk (NVO).

I will call `market_view` on Viking Therapeutics (VKTX), Structure Therapeutics (GPCR), and Amgen (AMGN) to see their financial and market statuses. Let's do VKTX first.

I will now pull the market view for Structure Therapeutics (GPCR).

I will now pull the market view for Amgen (AMGN).

Now I will do some web searches regarding recent developments on the core companies and the broader GLP-1 dynamics. Specifically, let's look for: 1. Novo Nordisk's OASIS-5 clinical trial (lower doses of oral Wegovy pill) which was recently initiated. 2. Viking Therapeutics' pipeline updates (VK2735 Phase 3 oral or injectable, VK3019 DACRA, Phase 1 maintenance study). 3. Any legal updates regarding Kailera Therapeutics v. Structure Therapeutics Section 1782 discovery case or European patent dispute. 4. Any updates on the Novo Nordisk v. Eli Lilly advertising lawsuit in NJ. 5. Any pricing, reimbursement, or insurer coverage developments. Let's run a web search for Novo Nordisk OASIS-5.

I will fetch the Fierce Pharma and Reuters articles on the OASIS-5 trial. Let's start with Fierce Pharma.

Now I will fetch the Reuters article to see if there are any other details on OASIS-5.

Interesting, oral Wegovy (semaglutide) is already approved and launched as of late 2025/early 2026, and is doing very well. Let's see what the current findings say. The prior findings mention: `eli-lilly-foundayo-orforglipron-fda-approval`: Eli Lilly's Foundayo (orforglipron) FDA approval on April 1, 2026. Wait, let's read that note to see what the state of oral Wegovy is. I will call `read_notes` to see the exact text of our notes, or just pull the notes. Let's list the notes first.

This is very helpful. So we have: - `eli-lilly-foundayo-orforglipron-fda-approval` tracks the clash between Eli Lilly's Foundayo and Novo's Wegovy pill. - `viking-therapeutics-oral-vk2735-phase-2-venture` tracks Viking Therapeutics' clinical pipeline. Let's see if Viking has any news on the Phase 1 maintenance study of VK2735, which was expected in Q3 2026. - Let's see if there are any updates on Kailera v. Structure (`oral-glp1-patent-litigation-kailera-structure`). - Let's see if there are any updates on the Novo Nordisk v. Eli Lilly advertising lawsuit (`novo-nordisk-eli-lilly-advertising-lawsuit`). - Let's check for any updates on Viking Therapeutics' dual amylin/calcitonin receptor agonist (DACRA) VK3019 or the oral VK2735 Phase 3 trial. - Let's check for any updates on Amgen's MariTide or other pipeline developments. Let's do a search on Viking Therapeutics to see if there is any fresh news regarding VK2735 maintenance data or other developments since early August.

Let's do a search on Viking Therapeutics' second quarter earnings report or any recent press release to see if they've released the Phase 1 maintenance study results yet, since the watch was for Q3 2026. Wait, let's search specifically for the maintenance study readout or news in August 2026.

Let's fetch the Q2 2026 financial results of Viking Therapeutics to see what's in there. I will also check the August 2026 corporate presentation if possible, or search for any other press release. Let's fetch the Q2 results press release.

Let's check if there are any other news or press releases from Viking in August 2026. Let's search for "Viking Therapeutics" "maintenance" with freshness limit "month" or "week". Or just search without a limit. Let's do a search for Viking Therapeutics news releases.

Okay, so Viking has not yet released the maintenance dosing data as of today, August 24, 2026, but they reaffirmed in their Q2 earnings release on July 29, 2026, that data is expected "later this quarter" (meaning Q3 2026). So the watch `Viking Therapeutics Q3 2026 VK2735 Phase 1 Maintenance Study Readout` is still open and active. Let's do a search on Kailera Therapeutics and Structure Therapeutics to see if there are any updates on their Section 1782 discovery case or European patent litigation. Let's do a search.

Ah, look at the Pacermonitor / Govinfo results: `Kailera Therapeutics, Inc. v. Structure Therapeutics, Inc. et al` Case No. `3:2026mc80216` in the Northern District of California. Let's search for "USCOURTS-cand-3_26-mc-80216-1" or search for "Kailera" "Structure" "3:26-mc-80216" to see if there is an order or a docket update. Let's do a search on Google.

Let's search for "Kailera" "Structure" "1782" "order" or look at the Justia docket link: `https://docs.justia.com/cases/federal/district-courts/california/candce/3:2026mc80216/474787/9`. Wait, let's search for more details on the docket. Is there any substantive ruling on the Section 1782 application? Let's search on Google.

Let's search for "ORDER re" "EX PARTE APPLICATION for Section 1782" "Kailera" on Google. Or search for "Thomas S. Hixson" "Kailera" "Structure". The judge is Thomas S. Hixson (TSH). Let's see if there is any other order on the docket. Let's do a search for: `"Thomas S. Hixson" OR "TSH" "Kailera" "Structure"` or `"3:26-mc-80216"` on Google.

Let's search for "ORDER re 1 EX PARTE APPLICATION for Section 1782" on Google or Justia. Let's see what happened on July 23, 2026. Wait, let's search for: `"ORDER re 1 EX PARTE APPLICATION" "Kailera"` on Google.

Let's check if the application was granted or denied. Let's do a search for: `"1 EX PARTE APPLICATION" "Kailera" "granted" OR "denied"` or `"Section 1782" "Kailera" "granted" OR "denied"`.

Ah, the web_search budget is spent. No problem, we can use the information we have, plus our market views and prior findings, to write up our findings and update the status of our watches. Let's review the findings we should write or update: 1. **Novo Nordisk's OASIS-5 trial for lower maintenance doses of oral Wegovy pill (semaglutide)** is a major new development. - We retrieved two excellent articles: Fierce Pharma (August 20, 2026) and Reuters (August 19, 2026). - This trial, OASIS-5, was initiated on August 12, 2026, and is scheduled to run until 2028. It will enroll 450 overweight or obese adults without diabetes to evaluate lower maintenance doses than the currently approved 25 mg strength. - This represents a critical pivot in the oral GLP-1 space: addressing the consumer trend of "microdosing" to manage side effects and high costs, and preparing for long-term chronic maintenance. - We can write a new note or update an existing one. Let's see if we have a note on oral GLP-1s. Yes, `eli-lilly-foundayo-orforglipron-fda-approval` tracks the "Oral GLP-1 Showdown" between Lilly's Foundayo and Novo's Wegovy pill. This is the perfect note to update! - In the latest quarter, oral Wegovy recorded sales of 3.22 billion Danish kroner (~$497 million to $499.89 million), while Lilly's newly launched oral Foundayo recorded sales of $98 million. - We will update `eli-lilly-foundayo-orforglipron-fda-approval`. Let's read the note's existing content first to make sure we integrate it correctly and don't overwrite unrelated important details. Wait, we can't search more, but we can write the note with the same slug, which will update it. Let's write the note. Wait, let's look at the other findings we can write: 2. **Viking Therapeutics' Q2 2026 Financial Results and Obesity Pipeline Progress**. - We fetched Viking's official Q2 2026 financial results press release (July 29, 2026). - They had a strong quarter-end cash position of $502 million. - They reported R&D expenses of $115.8 million for the quarter and a net loss of $128.0 million ($1.10 per share). - They confirmed that Phase 3 VANQUISH-1 and VANQUISH-2 trials for subcutaneous VK2735 in obesity are fully enrolled and proceeding according to plan. - They plan to initiate the Phase 3 oral VK2735 trial in 4Q2026. - They plan to release data from the exploratory Phase 1 maintenance dosing study of VK2735 in 3Q2026 (later this quarter). - They have initiated the Phase 1 trial for their novel amylin receptor agonist VK3019 (DACRA). - We should update `viking-therapeutics-oral-vk2735-phase-2-venture` with these details. Let's check if there are any other notes we should write or update. Wait, let's write the update to `eli-lilly-foundayo-orforglipron-fda-approval` first. Let's make sure we have the exact figures and quotes: - From Fierce Pharma: - "OASIS 5 is designed to evaluate the efficacy and safety of lower maintenance doses of the Wegovy pill in adults with overweight or obesity," Novo said in an email to Fierce. "While the currently approved maintenance dose is 25 mg, we are also studying the effects of lower maintenance doses by generating new evidence to fully reflect the patients’ needs in real-world obesity management." - "In the second quarter, the oral drug clinched sales of 3.22 billion Danish kroner ($497 million), far outdistancing those of Eli Lilly’s GLP-1 pill Foundayo, which was launched in early April and accounted for sales of $98 million in the latest reported quarter." - From Reuters: - "Danish drugmaker Novo Nordisk NOVOb.CO is testing smaller doses of its Wegovy pill in a new late-stage study to find the lowest dose that would still help patients lose weight..." - "The OASIS-5 study, which began on August 12 and runs until 2028, will test lower strengths of the daily maintenance dose used to keep weight off." Let's call `write_note` for `eli-lilly-foundayo-orforglipron-fda-approval`. Let's draft it beautifully.

Excellent! Now let's update Viking Therapeutics' note `viking-therapeutics-oral-vk2735-phase-2-venture`. Let's see what the main points are: - In its Q2 2026 financial results reported on July 29, 2026, Viking Therapeutics (VKTX) reported a net loss of $128.0 million ($1.10 per share) and R&D expenses of $115.8 million, primarily driven by clinical trial costs. - The company maintains a strong cash position of $502 million in cash, cash equivalents, and short-term investments (as of June 30, 2026). - Clinical pipeline updates: - Phase 3 VANQUISH-1 (obesity) and VANQUISH-2 (obesity + Type 2 diabetes) trials evaluating subcutaneous VK2735 are fully enrolled and proceeding on schedule. - Initiation of the Phase 3 clinical trial evaluating the oral formulation of VK2735 is expected in 4Q2026. - Data from the exploratory Phase 1 maintenance dosing study of VK2735 (evaluating biweekly, monthly, or oral/subcutaneous maintenance regimens) is expected in 3Q2026 (later this quarter). - Initiated the Phase 1 trial for its novel dual amylin/calcitonin receptor agonist (DACRA) VK3019 on June 24, 2026, expanding its obesity franchise beyond the incretin pathway. - Let's write the note.

Both notes have been written and updated beautifully! Let's see if there are any other updates we need to make. Wait, let's look at our watches. 1. `Viking Therapeutics Q3 2026 VK2735 Phase 1 Maintenance Study Readout` is still open and active. 2. `Viking Therapeutics Oral VK2735 Phase 3 Trial Initiation` is expected in 4Q2026 (still open). 3. `Viking Therapeutics VK3019 Phase 1 SAD Obesity Trial Readout` is expected in 2027 (still open). 4. `Kailera v. Structure Section 1782 Discovery Ruling` - We saw that there was an ex parte application filed on July 22, 2026, and an order was issued on July 23, 2026, by Judge Thomas S. Hixson. We don't have the exact text of whether it was granted or denied, but we see that several attorneys have been admitted pro hac vice and the case is active. This watch is still open since a final ruling or discovery production hasn't fully resolved the patent dispute. Wait, let's keep it open. 5. `Novo Nordisk Wegovy and Ozempic $675 List Price Cut Implementation` is expected on January 1, 2027 (still open). 6. `Eli Lilly Retatrutide Regulatory Submission in Obesity and Comorbidities` is expected in Q1 2027 (still open). 7. `Structure Therapeutics Aleniglipron Body Composition and SWITCH Trial Readouts` is expected in Q4 2026 (still open). 8. `Amgen MariTide Type 2 Diabetes Phase 3 Trial Initiations` is expected by the end of 2026 (still open). 9. `Novo Nordisk v. Eli Lilly Preliminary Injunction Ruling on GLP-1 Ads` is expected by late 2026 (still open). 10. `Eli Lilly Foundayo (Orforglipron) Europe and UK Commercial Launch` is expected in late 2026/early 2027 (still open). 11. `Amgen 2010–2015 IRS Tax Court Ruling` is expected in H2 2026 (still open). Let's double-check if we need to record any new threads or watches. Wait, we have recorded everything nicely. Let's call `finish_cycle` to complete this research cycle. Since we wrote findings, we do not need to pass `no_findings_reason`. Let's end the cycle.

I have completed the research cycle for this topic. Here is a summary of the key findings and updates: ### 1. Oral GLP-1 Commercial and Clinical Dynamics I updated the note **[[eli-lilly-foundayo-orforglipron-fda-approval]]** to capture the major commercial and clinical developments in the once-daily oral GLP-1 space: * **Commercial Showdown:** In the second quarter of 2026, Novo Nordisk's oral **Wegovy** (semaglutide) tablet demonstrated robust momentum, generating **3.22 billion Danish kroner (~$497 million to $499.89 million)** in sales. Meanwhile, Eli Lilly's once-daily oral GLP-1 **Foundayo** (orforglipron), which was approved by the FDA on April 1, 2026, and launched in early April, recorded **$98 million** in sales during its first partial quarter. * **OASIS-5 Clinical Trial:** On **August 12, 2026**, Novo Nordisk initiated the late-stage **OASIS-5 study** (NCT07770841) to evaluate lower maintenance doses of oral Wegovy. The 60-week, 450-patient placebo-controlled trial aims to find the lowest effective dose for long-term weight maintenance, addressing the popular real-world trend of patient "microdosing" to manage side effects and high pharmacy costs. ### 2. Viking Therapeutics Pipeline and Financial Progress I updated the note **[[viking-therapeutics-oral-vk2735-phase-2-venture]]** to integrate Viking's Q2 2026 financial results and clinical milestones: * **Financial Position:** Viking reported a second-quarter net loss of **$128.0 million** ($1.10 per share) as R&D expenses ramped to **$115.8 million** (up from $60.2 million in Q2 2025) to fund late-stage clinical programs. The company remains well-funded with **$502 million** in cash, cash equivalents, and short-term investments as of June 30, 2026. * **Clinical Milestones:** * **Subcutaneous VK2735:** The Phase 3 **VANQUISH-1** (obesity) and **VANQUISH-2** (obesity + Type 2 diabetes) trials are fully enrolled and proceeding on schedule. * **Oral VK2735:** Viking expects to initiate its Phase 3 oral obesity trial in the **fourth quarter of 2026**. * **Maintenance Dosing:** Topline data from the exploratory Phase 1 maintenance dosing study of VK2735 is expected **later in the third quarter of 2026**. * **VK3019 (Amylin Agonist):** Viking initiated a Phase 1 single ascending dose (SAD) trial on **June 24, 2026**, evaluating VK3019—an investigational dual amylin/calcitonin receptor agonist (DACRA)—expanding its pipeline beyond incretin-based dual agonists.